Rosuvastatin (Crestor)
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia, Atherosclerosis
Trial Timeline
Mar 1, 2009 โ Mar 1, 2012
NCT ID
NCT00885872About Rosuvastatin (Crestor)
Rosuvastatin (Crestor) is a approved stage product being developed by AstraZeneca for Hyperlipidemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00885872. Target conditions include Hyperlipidemia, Atherosclerosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00885872 | Approved | UNKNOWN |
Competing Products
20 competing products in Hyperlipidemia